Podcasts about Delta

Im vergangenen September, am 16. ganz genau, wäre er 100 Jahre alt geworden: B.B.King. Vater und Mutter waren Farmpächter, er selbst Traktorfahrer, wurde zum König des Blues, mit unzähligen Schallplatten und CDs, 1957 die erste, 2008 die letzte, insgesamt 43. Geboren in einem Weiher namens Berclair, Mississippi, aufgewachsen in Indianola, Mississippi, ging er 1946 nach Memphis, Tennessee, arbeitete als DJ, war Teil der Blues-Szene der Beale Street (dem Vergnügungsviertel der Afro-Amerikaner), machte Aufnahmen bei Sun-Record und wurde ein Freund von Elvis. King steht für eine Musik aus einer Gegend, die man Delta nennt, Mississippi Delta. Wir sind in Memphis, in einem seiner Clubs, dem "B.B.King's Blues Club", unsere Reise geht nach Indianola, wo es seit einigen Jahren das "B.B.King Museum and Delta Interpretive Center" gibt, und wir lernen eine seiner Töchter kennen, die, mit ihrem Vater auf Tour, an ein paar Orte in Deutschland erinnert. Eine Zeitreise, eine Zeitgeschichte somit, eine Geschichte des einzigen Blues-Musikers, der, im Zusammenhang mit der Geschichte der Südstaaten, sein eigenes Museum hat. Und dort auch begraben liegt.

 Join host Elisabeth Carson as she sits down with master dowser and geomancer, Maria Wheatley, to dive deep into the repressed history and hidden energies of the world's most sacred sites, including Stonehenge, the Great Pyramid of Giza, and Avebury.Maria Wheatley, who inherited the archives of master dowsers and is a highly respected expert on megaliths worldwide, shares incredible revelations you won't hear in a mainstream tour:

con Denise Cicchitti e Giuliano Gomez

Welcome to the Bamgboshe Happy Hour Pop Edition!

The news was messy this week and I'm here to unpack it all so you don't have to pretend you understand what's happening. Trump signs the Epstein files bill, giving the DOJ 30 days to release sensitive documents, then drops support for Marjorie Taylor Greene, and fresh details surface in Matt Gaetz's controversial case. Elon Musk claims his robots could replace surgeons and revolutionize healthcare, while the Dept. of Education proposes removing graduate nursing and other health programs from professional degree lists. The Trump administration plans SNAP reapplications to curb fraud, and a pardoned Jan 6 rioter faces new legal trouble. We cover major legal developments, including O.J. Simpson's estate paying $58M to Ron Goldman's family, and high-profile arrests like RHOP alum Mia Thornton allegedly stealing $11K in furniture. Plus, Porsha Williams involved in a Delta flight altercation, Nicki Minaj speaks at the UN regarding Nigeria while the U.S. military operations impact Trinidad, her home country, and Haiti's historic return to the World Cup after 51 years. Tune in for a whirlwind of current events. IG: itswista Podcast IG: wordswithwista SubStack: wordswithwista

In this powerful episode of the Healthy Hustle Podcast, Rachel sits down with Dr. Patrick K. Porter, a neuroscience expert, inventor of BrainTap®, and founder of BrainTap Technologies. With decades of experience helping over 120,000 people—including pro athletes, veterans, and high achievers—Dr. Porter shares practical, science-backed strategies to boost focus, improve sleep, and build resilience so you can show up as your best self in life and business. His work blends brainwave science, visualization, and neuroplasticity to make peak mental performance achievable for everyone. If you've been feeling overwhelmed, burned out, or stuck in chronic stress, this conversation is a MUST listen. Dr. Porter breaks down complex brain science into simple, actionable steps that anyone can use—starting today. What You'll Learn in This Episode 1. Your Brain Is More Powerful Than You Realize How every cell in your body is constantly "listening" to your environment—thoughts, foods, people, light, sound, and stress—and mirroring it back through your biology. Why your DNA is continually updating based on how you perceive life: as a threat or as a challenge. 2. Why Stress Isn't Just a "Mindset" Problem The link between chronic stress and disrupted neurotransmitters, sleep cycles, gut health, and blood sugar. Why Dr. Porter says we don't have a mental health crisis—we have a physiological crisis. 3. Brainwaves 101: Understanding Your Inner Operating System Dr. Porter breaks down: Beta – reactionary, can be tied to fear, frustration, anxiety. Alpha – daydreaming, creativity, presence, flow. Theta – deep relaxation, super-learning, memory integration. Delta – deep sleep and brain detox. Gamma – the "bass drum" that helps keep the whole brain orchestra in sync. You'll hear how modern life pushes many people out of balance—and what that looks like in everyday symptoms (brain fog, burnout, poor focus, anxiety). 4. The Science Behind BrainTap® You'll learn how BrainTap uses light, sound, and vibration to: Support brainwave balance Increase ATP (cellular energy) Improve sleep architecture and deep delta sleep Regulate the nervous system Support gut-brain communication and overall resilience Dr. Porter also dives into: Red light therapy and mitochondrial energy Circadian rhythms and why timing of sleep matters Why a 2 PM "reboot" can increase productivity by 26% 5. A Daily BrainCare Routine You Can Start Now Dr. Porter outlines a simple structure you can plug into your day: Morning: a short "digital coffee" BrainTap session to energize the brain without relying on caffeine. Midday (around 2 PM): a 20-minute reboot session to reset your nervous system and restore focus. Evening: a session that guides your brain into delta for deeper, more restorative sleep. Plus, a simple 4–8 breathing practice before bed to activate the parasympathetic nervous system. Try BrainTap Free Dr. Porter offers a 14-day free trial of the BrainTap app. No headset required to start Just your phone + audio Most people report noticeably better sleep by night three

On this week's show Sean talks Delta fishing with Captain Richard Rutland.

H4-Thur11/20/25-TCJS- " calls on the WORD talk line about Delta 9 and THC" , " calls on the WORD talk line about Delta 9 and THC" , " calls on the WORD talk line about Delta 9 and THC" , " calls on the WORD talk line about Delta 9 and THC"

Thursday, November 20th , 2025 - The Charlie James Show HOUR 1 1st - We got some big jobs numbers, The Trump economy is doing alright 2nd - Trump is the only one that happens to been doing anything. 3rd - The Democrats are hoping to take back the House & Senate 4th - We've been telling you the fewer the ingredients the better. HOUR 2 5th - Gene on WORD talk line about meeting with Trump by Mamdani 6th - Do you believe that A.I. should take up some of the Gov't slack? 7th - interview with Rep Sheri Briggs about Epstein files and Charlotte ICE 8th - Calls about Delta 9 and THC on the WORD talk line. HOUR 3 9th - interview with Mike Brest, Defense Reporter at the Washington Examiner 10th - calls on the WORD talk line about Delta 9 and THC 11th - calls on the WORD talk line about Delta 9 and THC 12th - calls on the WORD Talk line about Delta 9 and THC HOUR 4 13th- calls on the WORD talk line about Delta 9 and THC 14th- calls on the WORD talk line about Delta 9 and THC 15th- calls on the WORD talk line about Delta 9 and THC 16th- calls on the WORD talk line about Delta 9 and THC

Un total de 68 famílies de Deltebre s’han beneficiat del nou servei d’acollida matinal que ha impulsat l’Ajuntament amb l’objectiu de facilitar la conciliació familiar. Els actes començaran a les 18 h a la plaça Mossèn Gabriel Zapater amb un concert de Golden Groves, el grup de versions de l’Espiga d’Or. Recordem que Frame Film Festival fa parada este cap de setmana a Sant Jaume d’Enveja, l’última abans de la final del gener.

‘Arran de mar', realitzat per l'emissora local de la ciutat junt a d'altres sis ràdios municipals de Catalunya (Ràdio Arenys, Canal Blau FM, La Cala Ràdio, Delta.cat, Ràdio L'Escala, i Ona Malgrat) i amb coproducció de La Xarxa. Totes les emissores implicades comparteixen la proximitat i la passió pel mar i tot el que l'envolta. podcast recorded with enacast.com

Simon Silence negli studi di Delta 1 presenta "Pandora" con Daniele Di Ianni.

Laura Negre, coneguda com “La Galana”, és una emprenedora del delta de l’Ebre que ha creat La Galana SL a Sabadell, una botiga de productes alimentaris i tastos gastronòmics, i La Galana Rural SL, dedicada a càtering i esdeveniments al Delta, combinant negoci, creativitat i vincle familiar.

Una xerrada telefònica de dos amigues del delta de l'Ebre per saber tot el que passa a #Deltebre #Camarles #LAmpolla i #SantJaume. L’Infopòdcast és un espai informatiu coproduït amb la @laxarxacat en el que repassem la setmana a Delta.cat. En este capítol repassem l’actualitat de la setmana del 17 al 21 de novembre. I, també us proposem agenda!

The episode opens with a surge of breaking national news as President Donald Trump signs a bill ordering the Department of Justice to release its long-protected Jeffrey Epstein case files—triggering a 30-day countdown for roughly 100,000 pages of documents to be made public. The team also reviews newly released body-cam footage from Porsha Williams’ Delta flight confrontation, with the transcript revealing sharply different accounts of who escalated the incident. Things turn emotional when Rickey leads a raw discussion about a viral Chicago video showing a pregnant mother and her son being brutally attacked—sparking national outrage and raising difficult questions about accountability, parenting, and community safety. On a lighter note, Martha Stewart and Snoop Dogg revive their long-running partnership with a playful new gin-and-juice collaboration, proving their unexpected friendship still sells. Sports and trending topics round out the show, including updates on Jaylen Hurts and encouraging medical news on Jets cornerback Kris Boyd’s recovery after a recent shooting. The episode balances heavy national conversations with entertainment, humor, and heartfelt commentary in classic RSMS fashion. See omnystudio.com/listener for privacy information.

The team also reviews newly released body-cam footage from Porsha Williams’ Delta flight confrontation, with the transcript revealing sharply different accounts of who escalated the incident.See omnystudio.com/listener for privacy information.

What's Wrong with morning coffee and the changing face of Americans? Was an Otter kidnapped? Meat clever smuggled on Delta flight, masked men delivering threatening Christmas cards in California, parents raising kids without technology, Kevin Spacey is going broke, the Eddie Murphy doc and former Olympic snowboarder turned drug kingpin. 

A listener wrote to us: "I'm a United employee, so I do enjoy hearing about how much everyone except UA and DL sucks. That said, a more challenging series of episodes might be 'what's wrong with DL or UA'...so tell us where you think we suck, and you might as well do a similar episode for the other two airlines that are doing well." This week: Brian Sumers and Brett Snyder do just that, for Delta.We would like to thank SES for sponsoring The Air Show.Questions, responses or feedback? Visit www.theairshowpodcast.com to get in touch with us.

Federal hemp crackdown, gas station gummies, and THC alphabet soup, all rolled into one Sesh.In this episode, Brandon and Jesse spark up some loud Larry OG and unpack what the new federal move to pull “minor” cannabinoids off the shelves really means, not for lobbyists, but for the people actually eating these gummies and hitting these pens.You hear a lot about “Delta this, THC that,” but nobody explains who gets safer and who just gets pushed deeper into the shadows. So we do.What we get intoWhat the feds are trying to ban next year, including delta 8, THC O, HHC, THCP and other synthetic hemp cannabinoids that get you liftedWhy most of these lab-cooked cannabinoids feel nothing like whole plant cannabis, and why real consumers rarely touch gas station “hemp highs”The THCa loophole, how companies ship “legal weed” through the mail, and why the farm bill accidentally created a nationwide grey marketHow bans on flavored nicotine vapes, spice, kratom and now synthetic cannabinoids keep pushing people toward sketchier, unregulated productsWhy kids are not walking into Chevron to buy these products, and how lawmakers keep legislating optics instead of outcomesThe difference between regulation and prohibition, and how overtaxing and overregulating cannabis states like California actually feed the black marketA real talk side quest on psilocybin as a sacred tool, not a party favor, and what integration looks like after a heavy journeyNarcan vending machines, cough syrup highs, Sudafed IDs, and the weird lengths people go just to feel somethingQuestions we throw at each other, and at youDoes banning cannabinoids like HHC, THC O or THCP actually make anyone safer, or does it just crank up curiosity and push it undergroundShould ultra-potent cannabinoids ever be on gas station shelves, or only in tightly regulated medical settingsIs THCa really different from “normal” cannabis in any way that matters, or is it just a label game that lets some states pretend it is not weedWill this hemp crackdown empty shelves next year, or will we just see THC 10, THC 11 and THC “whatever is still legal” pop up insteadIf you live in a hemp only state, what does this change for you, and do you end up safer, screwed, or just more confusedIf you have ever grabbed a random “hemp gummy” from a smoke shop, live in a state with no legal cannabis, or know someone who thinks delta 8 is “diet weed,” this episode gives you the context nobody at the counter is telling you. We are not fearmongering, we are just tired of people getting wrecked by products that exist purely because our laws are written by people who do not understand the plant or the culture.This one is for anyone stuck in the loopholes.Save on Dr Dabber with Code: Cannabisschool10Save on Storz & Bickel with Code : CannabisschoolSave on Santa Cruz Shredder with Code: CSP10Save on Bomb Erigs with Code: CSPScore 100 on your test

In this episode of The Property Profits Podcast, Dave Seymour shares how he and his team at Freedom Venture uncover real estate opportunities using a strategy he calls “Delta Picking.” From distressed assets to retail repositioning and investor education, Dave reveals the real math behind smart deals—and how his Legacy Wealth Masterclass is helping professionals become savvy investors. - Get Interviewed on the Show! - ================================== Are you a real estate investor with some 'tales from the trenches' you'd like to share with our audience?   Want to get great exposure and be seen as a bonafide real estate pro by your friends?  Would you like to inspire other people to take action with real estate investing?  Then we'd love to interview you!  Find out more and pick the date here:   http://daveinterviewsyou.com/   #realestate #multifamily #commercialrealestate #investortraining #passiveincome

Emerald Downs is open seven days a week for full card simulcasting. Follow many of the top horses and trainers from our 2025 meeting at Turf Paradise, whose schedule includes Monday and Tuesday racing. Many other tracks in operation include Del Mar, Aqueduct and Churchill Downs with Tampa and Fair Grounds opening this week. 2026 Emerald Downs racing dates are official – May 2 to September 7. Vince goes over the all the details . This week's guests include Delta Downs Track Announcer and Handicapper Don Stevens, who speaks to Delta's upcoming, all-wager 10% takeout days. Those wagers are effective next Tuesday and Wednesday, Nov. 25-26, first race 10:55 am EmD time. There's also Joe Nevills, Bloodstock Editor for the Paulick Report. Nevills is a Thoroughbred fan from his young days in Michigan and he enthusiastically goes over some under-the-radar sires and previews his “All Value Sire Team,” reports coming on December 1.

Send us a textNorwegian-Today's B1 Word: [Å delta] Prepping for the Norskprøven (the Norwegian language test)? Spend one minute with us every day to master key B1 vocabulary!

Kevin Spacey says he's now homeless after losing his Baltimore home and most of his fortune to legal battles but insists he's not bankrupt. Justin Bieber stops on the side of the road to help a stranded driver in a viral act of kindness. “Real Housewives of Potomac” alum Mia Thornton is arrested in Atlanta for allegedly stealing $11,000 worth of furniture from a condo. Porsha Williams says her Delta flight altercation began over phone volume — not violence — as the FBI investigates. Hosts: Charlie Cotton, Deven Rall Learn more about your ad choices. Visit podcastchoices.com/adchoices

H3-Seg2-Thur11/20/25-TCJS- calls on the WORD talk line about Delta 9 and THC

H4-Seg2-Thur11/20/25-TCJS- calls on the WORD talk line about Delta 9 and THC

H4-Seg1-Thur11/20/25-TCJS-calls on the WORD talk line about Delta 9 and THC

H2-Thur11/20/25- "Gene on WORD talk line about meeting with Trump by Mamdani " , "Do you believe that A.I. should take up some of the Gov't slack? " , "interview with Rep Sheri Briggs about Epstein files and Charlotte ICE " , " Calls about Delta 9 and THC on the WORD talk line."

H3-Thur11/20/25-TCJS- " interview with Mike Brest, Defense Reporter at the Washington Examiner " , " calls on the WORD talk line about Delta 9 and THC" , " calls on the WORD talk line about Delta 9 and THC" , " calls on the WORD Talk line about Delta 9 and THC "

Porsha Williams publicly responds to the viral story about her being escorted off a Delta flight, insisting she was the victim of a verbally aggressive passenger. Her legal team confirms the FBI is reviewing the incident, as the man reportedly made false allegations contradicted by multiple eyewitnesses. See omnystudio.com/listener for privacy information.

Tariff juggling - just moving them around - no studies, no rationale Big Moves - One of the worst Novembers since 2008 The Big Short - End of a Era? PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter   Warm-Up - Last Few Days for IBIT CTP - Closing Price This Friday - The Big Short - End of a Era? - What is happening to Bitcoin? - THC laws changing - interesting loophole closed Markets - Tariff juggling - just moving them around - no studies, no rationale - Big Moves - One of the worst Novembers since 2008 - Hindenburg Omen - Fed Losing Cred WHY? - If tariffs are not inflationary and this administration has brought down prices on groceries.... - President Trump signed an EO Friday lowering tariffs on beef, tomatoes, coffee and bananas, according to Bloomberg - So , just shooting from the hip on all of this are we? --- Seriously, where is the plan, where is the analysis, where are the results? Total horseshit More Tariffs - Switzerland and U.S. agree to trade deal; U.S. will lower tariffs to 15% from 39%; Swiss companies are planning to make direct investments in the USA amounting to $200 billion by the end of 2028 - Switzerland will reduce some import duties on US Imports - For other US export interests, a solution was agreed that takes Switzerland's agricultural policy interests into account: under the agreement, Switzerland will grant the US duty-free bilateral tariff quotas on selected US export products: 500 tonnes for beef, 1,000 tonnes for bison meat and 1,500 tonnes for poultry meat. - Furthermore, Swiss companies are planning to make direct investments in the USA amounting to $200 bln by the end of 2028. - What did we accomplish here? - Just going back to what it was with a slightly higher tariff on Swiss goods than before...BECAUSE WE WERE GETTING KILLED WITH FOOD COSTS Fed Update - Markets no longer view December as a sure bet - Lots of Fed speakers out with commentary that is hawkish - Currently, there is a 46% chance of a rate cut by 0.25% - a month ago it was at 95% - AND, they should not cut in the absence of all data (Stephan Miran looking for 0.50%, but he is a total tool) More Horseshit! - Former Federal Reserve Board Gov. Adriana Kugler broke the central bank's rules regarding stock trading, according to a report released by the U.S. Government Ethics Office. - Now we know why she abruptly resigned a few months ago - That disclosure shows two kinds of violations of Fed rules regarding financial transactions by senior officials at the central bank: purchases of stocks of individual companies, as opposed to mutual funds; and purchases of securities during so-called “blackout periods” leading up to and after Federal Open Market Committee meetings. - Oh - Supposedly her husband did it - but come on! - Fed losing more credibility - this is not the first time.... StampFlation - The Postal Service filed notice with the Postal Regulatory Commission for Shipping Services price changes to take effect Jan. 18, 2026. The proposed adjustments were approved by the governors of USPS this week. - The change would raise prices approximately 6.6 percent for Priority Mail service, 5.1 percent for Priority Mail Express service, 7.8 percent for USPS Ground Advantage and 6.0 percent for Parcel Select. BIG - Michael Burry, the investor whose successful bets against the U.S. housing market in 2008 were recounted in the movie "The Big Short," is closing his hedge fund, Scion Asset Management. - In a letter to investors dated October 27, a copy of which was seen by Reuters, Burry said he would liquidate the funds and return capital, "but for a small audit/tax holdback" by the end of the year. - "My estimation of value in securities is not now, and has not been for some time, in sync with the markets," Burry said in the letter. - Put on a big OPTIONS short on NVDA and PLTR - We checked and his Registration expired.. Has about $155 million under management - not so much.. - He hinted that he will be back doing something and will announce on November 25th... Softbank - We know that they CUT all of their NVDA holdings - Looking at the 13F, also cut ORCL - New position in INTC - Looking to raise significant cast to outlay to private companies over the next couple of months. - Stock is up 120% YTD, DOWN 12% last week - Did you know He had for many years the distinction of being the person who had lost the most money in history (more than $59 billion during the dot-com crash of 2000 alone, when his SoftBank shares plummeted), a feat surpassed by Elon Musk in the following decades. THC Blues ??? - A new ban, tucked into legislation ending the longest shutdown in history, outlaws products containing more than 0.4 milligrams of total THC per container. == Industry executives said that threshold will wipe out 95% of the $28 billion hemp retail market when it takes effect in a year. - 300,000 jobs could be effected ($28 billion annually) - Possible that state laws will win out, but clearly Federal laws are not going the way of the industry. - Concern that the blackmarket will grow again - However, this can be seen in several ways as it may be cleaning up some of the selling of things like Delta-8 those weird knock-offs seen at gas stations) UK Tax Scrap - British government bond yields rose sharply on Friday morning as investors react to reports that Finance Minister Rachel Reeves will scrap an expected increase in income tax. - The moves came as investors reacted to a report from the Financial Times of an income tax U-turn. - Remember that they did a similar plan a few years ago that caused major havoc with markets and currencies until they withdrew the idea. How Does This Work? - House Republicans drafting legislation that will redirect Affordable Care Act subsidies to individuals and away from health insurance companies, according to Politico Some Eco ...?? - Employment Situation for September 2025 that was supposed to be released on Friday, October 3, 2025, will now be release  Thursday, November 20, 2025 8:30 AM ET - What about October? White House says it may NEVER be released Hindenburg Omen - There was some excitement in the world of technical analysis the past two weeks as we saw 5 separate signals fire for something called the Hindenburg Omen. This is a warning signal of trouble, but trouble does not always come. What is fair to say is that Hindenburg Omen signals have appeared at every major stock market top going back several decades. - According to Tom McClellan: The current count of 5 signals is not as big as some other clusters. But we got 4 signals in a cluster at the end of 2021, ahead of the 2022 bear market. So 4 is enough, if the market is inclined to live up to this warning. And 2 signals were enough back in December 2024 and March 2025 to tell us about the trouble in the market which unfolded in the April 2025 tariff reaction minicrash. But 5 is better. Pied Piper - Losing Followers - OpenAi plans to invest $1.4 Trillion over the next 5 years or so - Biggest beneficiary - Oracle - Stock went from $250 to $340 overnight - now a $220 (Full Round-trip) - Oracle is looking to raise $38 billion in debt sales to help fund its AI buildout, according to sources with knowledge of the matter who asked not to be named because the information is confidential. Bloomberg reported on the planned debt raise last month. Disney Earnings - Hmmmmm...... - Shares fall 8% as revenue misses - Digging in for a prolonged flight with YouTube - The company also missed quarterly revenue expectations as the cable weakness overshadowed strong growth in the company's streaming and parks businesses central to its growth. - Family of 4 - Trip to Disney - A  3-night trip with tickets and dining is estimated to be between $6,000 and $9,000 Starbucks - Can it get any worse for this company? - Starbucks Workers United launched a strike in more than 40 cities and 65 stores on the day of chain's Red Cup Day sales event. - NY incoming Mayor Mandami says there should be a total boycott of the stores - The union is pushing for improved hours, higher wages and the resolution of hundreds of unfair labor practice charges levied against Starbucks. Buffett - Berkshire - Berkshire Hathaway revealed a $4.3 billion stake in Google parent Alphabet (GOOGL), and further reduced its stake in Apple (AAPL), detailing its equity portfolio for the last time before Warren Buffett ends his 60-year run as chief executive officer. - They also sold more Bank of America - *6% reduction - although still the thrid largest stockholder - Sold homebuilder DR Horton - Bought position in Domino's Pizza and Chubb ---- DPZ chart looks terrible Over to China - Economy not getting any better - Fixed-asset investment contracted 1.7% for the first ten months of the year, steepening from a 0.5% decline in the January-to-September period. - Retail sales climbed 2.9% in October from a year earlier, softening from a 3% year-on-year rise in September. - Industrial output expanded 4.9% in October, a slowdown from a 6.5% rise in the prior month. - The last time China recorded a contraction in fixed-asset investment was in 2020 during the pandemic, according to data going back to 1992 from Wind Information, a private database focused on the country. Electric Prices - We know that the new wave of data centers are requiring HUGE amounts of energy to keep them running - Residential utility bills rose 6% on average nationwide in August compared with the same period in the previous year, according to the U.S. Energy Information Administration.

In this episode, we speak with Dan Williams, Partner at Delta-v Capital, an investment firm focused on growth-stage software and technology services businesses. Founded in 2009, Delta-v Capital has provided flexible growth capital solutions to innovative companies across infrastructure software, cloud services, CxO software, and vertical software sectors for more than a decade. The firm manages over $1.3 billion in assets and maintains offices in Denver, CO, and Dallas, TX. Dan leads Delta-v's infrastructure software practice, focusing on cybersecurity, AI, and DevOps. He has led investments in companies including Arctic Wolf, Claroty, Corelight, Teamworks, CloudBees, LogRocket, and You.com, with successful exits such as Socrata and Venafi. Before joining Delta-v, Dan held product, engineering, and corporate development roles at Cisco and worked in the buyout group at American Capital. He holds a BS in computer science from MIT and an MBA with honors as a Palmer Scholar from the Wharton School. Dan was recently recognized as a Top Software Investor of 2025 by GrowthCap. I am your host, RJ Lumba. We hope you enjoy the show. If you like the episode, click to follow.  

 When You Refuse to Recognize Your Creator • Part of our midweek verse-by-verse study through Romans.

TurdOrTreasure is ThisWeekInGeek's dedicated review show covering everything from games to movies to tv to electronics and everything between!So please sit back and give a listen! There's likely something for everyone in this smorgasbord of a podcast! Show Links:Atari 50: The Namco Legendary Pack DLC (Switch And Xbox Review) https://www.digitaleclipse.com/games/atari-50-the-namco-legendary-pack-dlcBrass Dragon Bistro Candies (Candy Review) https://brassdragonbistro.com/collections/allD&D Welcome to the HellFire Club Boxset (RPG Book Review) https://marketplace.dndbeyond.com/category/4704000?pid=D4704000Metal Gear Solid Delta Snake Eater (Konami Game Review) https://www.konami.com/mg/mgs3r/gateOnce Upon A Katamari (Bandai Namco Review) https://www.bandainamcoent.com/games/once-upon-a-katamariElden Ring Nightreign (Bandai Namco Review) https://www.bandainamcoent.com/games/nightreignMillion Depth (Steam First Impressions Review) https://store.steampowered.com/app/2555950/Million_Depth/MotionRec (Steam First Impressions Review) https://store.steampowered.com/app/2602230/MotionRec/Dragon Blazers (Steam First Impression Review) https://store.steampowered.com/app/1160690/Dragon_Blazers/The Naked Gun (Paramount Bluray Review) https://www.blu-ray.com/movies/The-Naked-Gun-Blu-ray/400978/Spinal Tap II The End Continues (Bleecker Street Bluray Review) https://www.blu-ray.com/movies/Spinal-Tap-II-The-End-Continues-Blu-ray/400899/Your Geekmaster:Alex "The Producer" - https://bsky.app/profile/dethphasetwig.bsky.socialFeedback for the show?:Email: feedback@thisweekingeek.netTwitter: https://twitter.com/thisweekingeekBluesky: https://bsky.app/profile/thisweekingeek.bsky.socialYouTube: https://www.youtube.com/channel/UCc1BfUrFWqEYha8IYiluMyAiTunes: https://podcasts.apple.com/us/podcast/this-week-in-geek/id215643675Spotify: spotify:show:0BHP4gkzubuCsJBhU3oNWXCastbox: https://castbox.fm/channel/id2162049Website: https://www.thisweekingeek.netNovember 19, 2025

Escucha el podcast del programa Emprendoras by Mujeres de Hoy a través de Delta 103, en La Romana, República Dominicana correspondiente al miércoles 19-noviembre-2025.

Escucha el podcast del programa El Café de la Mañana a través de Delta 103, en La Romana, República Dominicana correspondiente al miércoles 19-noviembre-2025.

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

Worship leader and Passion artist Kristian Stanfill joins us to talk about the long road from addiction to five years of sobriety, the moment everything changed and how his new album 'Come to Jesus' was born from real healing and real joy.Cameron, Jesse, Derek and Emily also bring RELEVANT Buzz, our weekly breakdown of the latest at the intersection of faith and culture — and of course, we close the show with Slices, where the crew dives into the funniest, weirdest and most unexpected stories the internet has to offer.Show Highlights01:25 — Denver altitude, sinus infections & Cameron's Chap Stick disaster04:36 — The Colorado horse-ride saga and Derek's conspiracy theories08:55 — RELEVANT Buzz 09:00 — Daniel Caesar's faith-filled album hits the charts11:00 — The wild bike-prank video Jesse found on his cursed algorithm12:05 — Vine is officially coming back… sort of16:20 — Jenna Jameson gets baptized and shares her story18:15 — Guest: Kristian Stanfill joins the show18:45 — Why he made a solo album (Come to Jesus)21:00 — “I needed a revelation of Jesus” — Kristian on what actually changed him26:15 — What year four to year five of sobriety taught him27:20 — The power of community, vulnerability and refusing isolation28:15 — Advice for pastors, leaders and anyone afraid to ask for help31:20 — Does he get tired of talking about his darkest season?33:55 — Slices: A horse falls into a family's backyard pool39:20 — An AI song hits No. 1 on the country charts45:55 — Congress quietly bans Delta-8 and similar THC products48:20 — The dark side of unregulated synthetic drugsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

The show dives into controversy as Porsha Williams was escorted off a Delta Airlines flight, with the FBI confirming it is reviewing whether any federal charges apply. While details remain unclear, eyewitness reports and Delta’s own statement confirm two passengers were involved in an incident on board. See omnystudio.com/listener for privacy information.

The Rickey Smiley Morning Show Podcast kicks off with major entertainment news as Robin Roberts announces a new Roberta Flack biopic and documentary, honoring the late music legend whose timeless hits like “Killing Me Softly” and “The First Time Ever I Saw Your Face” shaped generations. Flack passed away earlier this year at 88 after complications from ALS. Meanwhile, the show dives into controversy as Porsha Williams was escorted off a Delta Airlines flight, with the FBI confirming it is reviewing whether any federal charges apply. While details remain unclear, eyewitness reports and Delta’s own statement confirm two passengers were involved in an incident on board. And in the biggest national headline of the day, the team breaks down Mark Epstein’s claim that Trump wants Epstein’s files released only after “sanitization.” In a recent NewsNation interview, Jeffrey Epstein’s brother alleged the files are being scrubbed to remove names tied to certain political figures, adding another twist to the long-running controversy surrounding Epstein’s death and associated investigations. Website: https://www.urban1podcasts.com/rickey-smiley-morning-show See omnystudio.com/listener for privacy information.

durée : 00:48:06 - Affaires sensibles - par : Fabrice Drouelle - Aujourd'hui dans Affaires sensibles, une catastrophe écologique et humaine, dans l'une des régions les plus polluées au monde : le delta du fleuve Niger, au Nigeria. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Delta Resources Chairman, Frank Candido, joined the pod for an update on the continued Phase II drilling program from the Delta-1 Project in Ontario. The company has been conducting big step-out drilling to define potential size and scale of the system. The program will include a minimum of 13 drill holes totaling over 3,100 metres, designed to expand the Eureka Gold Deposit and test satellite targets.

✨ Support the show with ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Premium (Ad-Free)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ -- Drift into deep, restorative rest with this 8-hour calming soundscape blending soft ambient guitar, soothing white noise, and gentle 3 Hz delta wave binaural beats. The peaceful guitar melodies create a warm, dreamy atmosphere, while the steady white noise masks distractions and quiets the mind. Beneath it all, 3 Hz delta waves guide your brain into the deepest stages of sleep—perfect for healing rest, stress reduction, and full-night relaxation. Best For: Deep sleep & insomnia relief Stress and anxiety reduction Meditation, mindfulness, and emotional release Creating a peaceful, cozy bedtime space Long, uninterrupted sleep cycles

FBI is reviewing Porsha Williams' Delta flight incident after altercation led to police escort off plane. Porsha's lawyer says she was verbally attacked by an “unhinged passenger” and will cooperate fully. Elon Musk claps back at Billie Eilish after she calls him selfish for “hoarding wealth,” calling her “not the sharpest tool.” Trump loses his cool over Epstein question mid-flight, calling reporter “Piggy” before defending his emails. Hosts: Deven Rall & Derek Kaufman Learn more about your ad choices. Visit podcastchoices.com/adchoices

Escucha el podcast del programa El Café de la Mañana a través de Delta 103, en La Romana, República Dominicana correspondiente al martes 18-noviembre-2025.

It was just another Delta L-1011 on the tarmac at Dallas-Fort Worth—except everyone on the ground crew knew this one had a history. Buried deep within its systems were replacement parts salvaged from Eastern Airlines Flight 401, the 1972 crash that killed more than a hundred people. The plane flew again—but not alone. Todd worked that jet for five years. And during that time, he and countless others began to see them: crew members who didn't belong to Delta… uniforms decades out of date… smiles that vanished into thin air. Whispers in the galley. Shadows in the reflection of cabin windows. Cold air that seemed to breathe. They weren't stories. They were sightings—repeated, documented, impossible to ignore. Maybe the crew of Flight 401 never left the sky. Maybe, for them, the flight just… kept going. #TrueGhostStory #Flight401 #HauntedPlane #EasternAirlines #AviationMystery #GhostStories #ParanormalActivity #RealHaunting #Supernatural #RealGhostStoriesOnline Love real ghost stories? Don't just listen—join us on YouTube and be part of the largest community of real paranormal encounters anywhere. Subscribe now and never miss a chilling new story:

Are you ready to WAKE! IT! UP! RuPaul's Drag Race star Kori King is in the house! Kori spills about attending the Emmys dressed as Michael Jackson, rocking Charlotte Russe dresses, and the chaos of her Cameo characters. Delta and Kori also bond over their shared love of a good brunch gig… just throw on Shania Twain and let the divas GIVE! Plus, Delta goes off on the medical company Apria. They rolled up to her house at 9:30 p.m. when they should've come correct, and honey... Delta DRAGS them straight through the mud.Listen to Very Delta Ad-Free AND One Day Early on MOM Plus⁠ ⁠Send us an e-mail at readmedelta@gmail.com⁠ FOLLOW DELTA⁠@deltawork⁠ ⁠VERY DELTA IS A FOREVER DOG AND MOGULS OF MEDIA (M.O.M.) PODCASTSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Are you worried about how easy it is for your tween, teen, or college-age child to get alcohol, weed, vapes, or “wellness” gummies—and not sure where to even start the conversation? In this episode of Power Your Parenting: Moms of Teens, Colleen talks with Pam Jenkins, Chief Executive Officer of Shatterproof, a national nonprofit dedicated to reversing the addiction crisis in the United States. Pam explains how today's substances (like Delta-8, synthetic THC products, and vaping) are more accessible and more potent, why mental health and substance use are so tightly linked, and why clear parental expectations are one of the strongest protective factors. You'll hear practical, hopeful ways to start ongoing conversations, monitor wisely (without turning into the “drug police”), and support your child's mental health so they're less vulnerable to addiction. About Pam Jenkins Pam Jenkins is the Chief Executive Officer of Shatterproof, the leading national nonprofit focused on preventing and treating addiction and supporting long-term recovery. With a lifelong career in public health and health communication, Pam has led large-scale initiatives in areas such as cancer, cardiovascular disease, and substance use. She has worked on government campaigns about marijuana, youth alcohol use, and created widely recognized public-health symbols like the red dress for women's heart disease. Today, Pam leads Shatterproof's policy advocacy, prevention programs, and family resources, all aimed at transforming how America understands and addresses addiction. 3 Key Takeaways for Moms Access and potency have changed—your expectations still matter. Teens can easily access highly potent substances (like Delta-8 and other synthetic THC products, vapes, and stronger marijuana) in gas stations, convenience stores, and online. Even so, clear parental disapproval is one of the strongest protections against teen use. Don't assume your kids “just know” how you feel—say it plainly and repeat it often. Mental health and substance use are inseparable. Anxiety, depression, ADHD, trauma, and social isolation all increase a teen's vulnerability to drugs and alcohol—and drug use can, in turn, worsen or even trigger serious mental health issues like crippling anxiety, depression, and psychosis. Monitoring your child's mood, behavior, friendships, grades, and social connectedness is as important as watching for the substances themselves. Monitor early, talk often, and stay curious—not panicked. Effective prevention starts young: secure medications at home, know your child's friends, stay engaged with school, and watch for changes in behavior or peer groups. Have many short, specific conversations—especially before parties or transitions—using curiosity (“What usually happens at those parties?”) rather than accusations. You don't have to be an expert; you just need to be present, clear about your values, and willing to keep the dialogue going well into their college years. Find out more at: https://shatterproof.org/ Follow at: https://www.instagram.com/weareshatterproof/ Learn more about your ad choices. Visit megaphone.fm/adchoices

What’s it like to spend the night in a fraternity??? We’ve got the hook ups and horror stories…and did anyone do the dreaded walk of shame?See omnystudio.com/listener for privacy information.

What’s it like to spend the night in a fraternity??? We’ve got the hook ups and horror stories…and did anyone do the dreaded walk of shame?See omnystudio.com/listener for privacy information.